Walleye Capital
ADVM

Walleye Capital’s Adverum Biotechnologies ADVM Stock Holding History

Walleye Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,369
Closed -$231K – 5524
2024
Q1 		$231K Buy
+16,369
New +$249K ﹤0.01% 3878
2021
Q4 		– Sell
-2,618
Closed -$57 – 2071
2021
Q3 		$57 Sell
2,618
-20,801
-89% -$531K ﹤0.01% 1381
2021
Q2 		$820 Buy
+23,419
New +$1.26M 0.03% 536
2020
Q4 		– Sell
-8,087
Closed -$833K – 914
2020
Q3 		$833K Buy
+8,087
New +$1.21M 0.09% 281
2020
Q1 		– Sell
-10,932
Closed -$1.26M – 853
2019
Q4 		$1.26M Buy
10,932
+7,952
+267% +$701K 0.08% 336
2019
Q3 		$163K Buy
+2,980
New +$336K 0.01% 1274

Other funds holding ADVM

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Walleye Capital's ADVM Position: Q2 2024 in Review

Walleye Capital sold out of Adverum Biotechnologies (ADVM) in Q2 2024, closing a stake of 16,369 shares — an estimated $231K sold.

Walleye Capital first reported a position in ADVM in Q3 2019 and held it in 6 quarters. The position peaked at $1.26M in Q4 2019. 68 funds tracked by Wall St. Rank hold ADVM as of Q2 2024.

  • Walleye Capital reported no remaining Adverum Biotechnologies position as of Q2 2024 after selling out during the quarter.
  • Walleye Capital sold 16,369 Adverum Biotechnologies shares in Q2 2024, an estimated $231K.
  • Walleye Capital first reported a position in Adverum Biotechnologies in Q3 2019 and held it in 6 quarters.
  • Walleye Capital's Adverum Biotechnologies position peaked at $1.26M in Q4 2019.
  • 68 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.